PIONEERING SMALL MOLECULE THERAPEUTICS

Alesta Therapeutics is a Netherlands and Boston-based biotechnology company
developing novel oral small molecule therapies for underserved rare diseases.
Our lead asset, ALE1, is being developed for hypophosphatasia (HPP), a rare
genetic disorder with significant unmet needs. We are also advancing ALE2, a
promising candidate to treat Charcot-Marie-Tooth (CMT) disease.

In January 2025 Alesta announced a €65 million Series A
financing supported by leading biotech and life science investors.

Leadership

Ilan Ganot

CEO

Matthias Van Woensel, PhD

CSO

Benit Maru, MBChB, PhD

CMO

Madhav Gurijala

Head of Operations

Board of Directors

Janwillem Naesens

Droia Ventures

Luc Dochez

Droia Ventures, Chairman

Laura Brass, PhD

Novartis Venture Fund

Ilan Ganot

Alesta Therapeutics, CEO

Dan Estes, PhD

Frazier Life Sciences

INVESTORS